PTC Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of PTC Therapeutics generated cash of -$158,418,000, which is more than the previous year. Cash used in financing activities reached the amount of $646,400,000 last year. Net change in cash is therefore $314,359,000.
Cash Flow
| 2014 | -57.27M | -145.16M | 237.12M |
|---|---|---|---|
| 2015 | -124.33M | -20.81M | 154.06M |
| 2016 | -103.56M | 104.48M | 968K |
| 2017 | -10.06M | 13.11M | 44.21M |
| 2018 | -27.64M | -42.61M | 131.57M |
| 2019 | -98.63M | -387.23M | 613.20M |
| 2020 | -194.07M | -561.54M | 668.71M |
| 2021 | -251.33M | 219.18M | 20.87M |
| 2022 | -356.65M | 290.18M | 167.95M |
| 2023 | -158.41M | -176.73M | 646.4M |
PTCT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 295.92M | 197.21M | 216.31M | 295.52M | 169.49M | 111.79M | 58.32M | 58.02M | 49.74M | 15.41M |
Operating activities | ||||||||||
Net income | -626.60M | -559.01M | -523.90M | -438.16M | -251.57M | -128.08M | -79M | -142.11M | -170.44M | -93.75M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 236.59M | 128.83M | 64.13M | 84.87M | 32.18M | 26.08M | 17.68M | 3.29M | 2.87M | 2.23M |
Stock-based compensation expense | 131.20M | 110.33M | 103.51M | 70.32M | 42.13M | 33.25M | 30.55M | 35.00M | 33.97M | 19.31M |
| Deferred income tax benefit | 131.20M | 110.33M | 103.51M | 70.32M | 42.13M | 33.25M | 30.55M | 35.00M | 33.97M | 19.31M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.53M | -48.46M | -44.99M | -10.48M | 11.52M | -29.58M | -12.20M | -14.84M | -6.90M | -3.48M |
Inventories | -8.18M | -6.66M | 1.8M | 1.84M | -3.45M | -5.82M | -6.45M | 893K | -1.97M | -2.62M |
Accounts payable | 48.34M | 27.54M | 23.41M | 53.58M | 13.74M | 43.10M | 24.01M | 4.25M | 16.98M | 16.91M |
Cash generated by operating activities | -158.41M | -356.65M | -251.33M | -194.07M | -98.63M | -27.64M | -10.06M | -103.56M | -124.33M | -57.27M |
Investing activities | ||||||||||
Purchases Of Investments | -212.48M | -75.55M | -543.26M | -1.44B | -494.06M | -68.61M | -81.36M | -85.37M | -223.76M | -247.80M |
Investments In Property Plant And Equipment | -28.43M | -152.46M | -85.33M | -55.97M | -45.43M | -15.53M | -3.10M | -1.77M | -2.72M | -4.66M |
Acquisitions Net | 0 | 128.43M | 57.11M | 38.13M | -4M | -48.89M | -77.16M | 0 | 0 | 0 |
Cash generated by investing activities | -176.73M | 290.18M | 219.18M | -561.54M | -387.23M | -42.61M | 13.11M | 104.48M | -20.81M | -145.16M |
Financing activities | ||||||||||
Common Stock Issued | 29.99M | 50M | 23.10M | 103.57M | 323.75M | 117.91M | 2.46M | 0 | 8.71M | 235.97M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -301.37M | 148.72M | -2.22M | -46.16M | 267.6M | 0 | 40M | 0 | 150M | -49K |
Cash used in financing activities | 646.4M | 167.95M | 20.87M | 668.71M | 613.20M | 131.57M | 44.21M | 968K | 154.06M | 237.12M |
Net Change In Cash | 314.35M | 98.70M | -19.09M | -79.21M | 126.03M | 57.70M | 53.47M | 299K | 8.27M | 34.33M |
Cash at end of period | 610.28M | 295.92M | 197.21M | 216.31M | 295.52M | 169.49M | 111.79M | 58.32M | 58.02M | 49.74M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |